Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Revance Therapeutics Releases Fourth Quarter And Full Year 2014 Financial Results And Reiterates 2015 Outlook - Yahoo Finance

The webcast will be available in the investor sweat disorder relations section on the Company's website for 30 days following the completion of the call. RT001 and http://sweatingguide.info/natural-home-remedies-for-sweaty-palms/ RT002 Product Candidates Revance is currently developing two botulinum toxin type A product candidates. RT001 is a topical formulation, which has the potential to be the first commercially available non-injectable dose form.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/revance-therapeutics-releases-fourth-quarter-210500437.html

Revance Appoints Dr. Philip Vickers to Its Board of Directors - Yahoo Finance

I am delighted to join them in this exciting stage of their development," said Dr. Vickers. Dr. Vickers joined Shire from Resolvyx Pharmaceuticals, where he was President and Chief Scientific Officer. While at Resolvyx, he was a member of the Board of Directors. Prior to Resolvyx, Dr. Vickers was Senior Vice President and U.S. Head of Research at Boehringer-Ingelheim Pharmaceuticals and he spent over 13 years with Pfizer in a number of R&D executive leadership positions.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/revance-appoints-dr-philip-vickers-220000463.html

Don't be the product, buy the product!